Inhibition of fatty acid synthase by amentoflavone reduces coxsackievirus B3 replication

Archives of Virology

Volumn 157, Issue 2, 2012, Pages 259-269

  Wilsky, Steffi ^a   Sobotta, Katharina ^a   Wiesener, Nadine ^a   Pilas, Johanna ^b   Althof, Nadine ^a   Munder, Thomas ^b   Wutzler, Peter ^a   Henke, Andreas ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF APPLIED SCIENCES JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMENTOFLAVONE; BIFLAVONOID; ENZYME INHIBITOR; FATTY ACID SYNTHASE;

ARTICLE; CELL LINE; COXSACKIE VIRUS INFECTION; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; ENTEROVIRUS; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; UPREGULATION; VIROLOGY; VIRUS REPLICATION;

BIFLAVONOIDS; CELL LINE; COXSACKIEVIRUS INFECTIONS; DOWN-REGULATION; ENTEROVIRUS B, HUMAN; ENZYME INHIBITORS; FATTY ACID SYNTHETASE COMPLEX; HUMANS; UP-REGULATION; VIRUS REPLICATION;

COXSACKIEVIRUS;

EID: 84856374797     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-011-1164-z     Document Type: Article

References (55)

1. Gupta S, Markham DW, Drazner MH, Mammen PP (2008) Fulminant myocarditis. Nat Clin Pract Cardiovasc Med 5(11): 693-706.
2. Badorff C, Knowlton KU (2004) Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside. Med Microbiol Immunol 193(2-3): 121-126.
3. Martin U, Nestler M, Munder T, Zell R, Sigusch HH, Henke A (2004) Characterization of coxsackievirus B3-caused apoptosis under in vitro conditions. Med Microbiol Immunol (Berl) 193(2-3): 133-139.
4. Heim A, Weiss S (2004) Interferons in enteroviral heart disease: modulation of cytokine expression and antiviral activity. Med Microbiol Immunol 193(2-3): 149-154.
5. Klingel K, Sauter M, Bock CT, Szalay G, Schnorr JJ, Kandolf R (2004) Molecular pathology of inflammatory cardiomyopathy. Med Microbiol Immunol 193(2-3): 101-107.
6. Rabenau HF, Richter M, Doerr HW (2010) Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany. Med Microbiol Immunol 199(1): 45-51.
7. Whitton JL, Cornell CT, Feuer R (2005) Host and virus determinants of picornavirus pathogenesis and tropism. Nat Rev Microbiol 3(10): 765-776.
8. Esfandiarei M, McManus BM (2008) Molecular biology and pathogenesis of viral myocarditis. Annu Rev Pathol 3: 127-155.
9. Vuorinen T, Vainionpaa R, Heino J, Hyypia T (1999) Enterovirus receptors and virus replication in human leukocytes. J Gen Virol 80(Pt 4): 921-927.
10. Mena I, Perry CM, Harkins S, Rodriguez F, Gebhard J, Whitton JL (1999) The role of B lymphocytes in coxsackievirus B3 infection. Am J Pathol 155(4): 1205-1215.
11. Vuorinen T, Vainionpaa R, Kettinen H, Hyypia T (1994) Coxsackievirus B3 infection in human leukocytes and lymphoid cell lines. Blood 84(3): 823-829.
12. Matteucci D, Paglianti M, Giangregorio AM, Capobianchi MR, Dianzani F, Bendinelli M (1985) Group B coxsackieviruses readily establish persistent infections in human lymphoid cell lines. J Virol 56(2): 651-654.
13. Jarasch N, Martin U, Zell R, Wutzler P, Henke A (2007) Influence of pan-caspase inhibitors on coxsackievirus B3-infected CD19+ B lymphocytes. Apoptosis 12: 1633-1643.
14. Klingel K, McManus BM, Kandolf R (1995) Enterovirus-infected immune cells of spleen and lymph nodes in the murine model of chronic myocarditis: a role in pathogenesis? Eur Heart J 16(Suppl O): 42-45.
15. Anderson DR, Wilson JE, Carthy CM, Yang D, Kandolf R, McManus BM (1996) Direct interactions of coxsackievirus B3 with immune cells in the splenic compartment of mice susceptible or resistant to myocarditis. J Virol 70(7): 4632-4645.
16. Kandolf R, Sauter M, Aepinus C, Schnorr JJ, Selinka HC, Klingel K (1999) Mechanisms and consequences of enterovirus persistence in cardiac myocytes and cells of the immune system. Virus Res 62(2): 149-158.
17. Magnani JW, Dec GW (2006) Myocarditis: current trends in diagnosis and treatment. Circulation 113(6): 876-890.
18. Henke A, Jarasch N, Wutzler P (2008) Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis. Expert Rev Vaccines 7(10): 1557-1567.
19. Esfandiarei M, Suarez A, Amaral A, Si X, Rahmani M, Dedhar S, McManus BM (2006) Novel role for integrin-linked kinase in modulation of coxsackievirus B3 replication and virus-induced cardiomyocyte injury. Circ Res 99(4): 354-361.
20. Esfandiarei M, Boroomand S, Suarez A, Si X, Rahmani M, McManus B (2007) Coxsackievirus B3 activates nuclear factor kappa B transcription factor via a phosphatidylinositol-3 kinase/protein kinase B-dependent pathway to improve host cell viability. Cell Microbiol 9(10): 2358-2371.
21. Feuer R, Mena I, Pagarigan RR, Hassett DE, Whitton JL (2004) Coxsackievirus replication and the cell cycle: a potential regulatory mechanism for viral persistence/latency. Med Microbiol Immunol 193(2-3): 83-90.
22. Rassmann A, Henke A, Zobawa M, Carlsohn M, Saluz HP, Grabley S, Lottspeich F, Munder T (2006) Proteome alterations in human host cells infected with coxsackievirus B3. J Gen Virol 87(Pt 9): 2631-2638.
23. Li Y, Webster-Cyriaque J, Tomlinson CC, Yohe M, Kenney S (2004) Fatty acid synthase expression is induced by the Epstein-Barr virus immediate-early protein BRLF1 and is required for lytic viral gene expression. J Virol 78(8): 4197-4206.
24. Wakil SJ (1989) Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28(11): 4523-4530.
25. Belov GA, Ehrenfeld E (2007) Involvement of cellular membrane traffic proteins in poliovirus replication. Cell Cycle 6(1): 36-38.
26. Kemball CC, Alirezaei M, Flynn CT, Wood MR, Harkins S, Kiosses WB, Whitton JL (2010) Coxsackievirus infection induces autophagy-like vesicles and megaphagosomes in pancreatic acinar cells in vivo. J Virol 84(23): 12110-12124.
27. van Kuppeveld FJ, Hoenderop JG, Smeets RL, Willems PH, Dijkman HB, Galama JM, Melchers WJ (1997) Coxsackievirus protein 2B modifies endoplasmic reticulum membrane and plasma membrane permeability and facilitates virus release. EMBO J 16(12): 3519-3532.
28. Lin YM, Anderson H, Flavin MT, Pai YH, Mata-Greenwood E, Pengsuparp T, Pezzuto JM, Schinazi RF, Hughes SH, Chen FC (1997) In vitro anti-HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora. J Nat Prod 60(9): 884-888.
29. Lin YM, Flavin MT, Schure R, Chen FC, Sidwell R, Barnard DL, Huffman JH, Kern ER (1999) Antiviral activities of biflavonoids. Planta Med 65(2): 120-125.
30. Ma SC, But PP, Ooi VE, He YH, Lee SH, Lee SF, Lin RC (2001) Antiviral amentoflavone from Selaginella sinensis. Biol Pharm Bull 24(3): 311-312.
31. Lee JS, Lee MS, Oh WK, Sul JY (2009) Fatty acid synthase inhibition by amentoflavone induces apoptosis and antiproliferation in human breast cancer cells. Biol Pharm Bull 32(8): 1427-1432.
32. Knowlton KU, Jeon ES, Berkley N, Wessely R, Huber S (1996) A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J Virol 70(11): 7811-7818.
33. Slifka MK, Pagarigan R, Mena I, Feuer R, Whitton JL (2001) Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection. J Virol 75(5): 2377-2387.
34. Verstrepen WA, Kuhn S, Kockx MM, van De Vyvere ME, Mertens AH (2001) Rapid detection of enterovirus RNA in cerebrospinal fluid specimens with a novel single-tube real-time reverse transcription-PCR assay. J Clin Microbiol 39(11): 4093-4096.
35. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9): e45.
36. Jarasch-Althof N, Wiesener N, Schmidtke M, Wutzler P, Henke A (2010) Antibody-dependent enhancement of coxsackievirus B3 infection of primary CD19+ B lymphocytes. Viral Immunol 23(4): 369-376.
37. Nissen E, Pauli G, Vollenbroich D (1997) WST-1 assay-a simple colorimetric method for virus titration. In Vitro Cell Dev Biol Anim 33(1): 28-29.
38. Ngamwongsatit P, Banada PP, Panbangred W, Bhunia AK (2008) WST-1-based cell cytotoxicity assay as a substitute for MTT-based assay for rapid detection of toxigenic Bacillus species using CHO cell line. J Microbiol Methods 73(3): 211-215.
39. Dowling S, Cox J, Cenedella RJ (2009) Inhibition of fatty acid synthase by Orlistat accelerates gastric tumor cell apoptosis in culture and increases survival rates in gastric tumor bearing mice in vivo. Lipids 44(6): 489-498.
40. Browne CD, Hindmarsh EJ, Smith JW (2006) Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. FASEB J 20(12): 2027-2035.
41. Gao F, Yue TL, Shi DW, Christopher TA, Lopez BL, Ohlstein EH, Barone FC, Ma XL (2002) p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. Cardiovasc Res 53(2): 414-422.
42. King EM, Holden NS, Gong W, Rider CF, Newton R (2009) Inhibition of NF-kappaB-dependent transcription by MKP-1: transcriptional repression by glucocorticoids occurring via p38 MAPK. J Biol Chem 284(39): 26803-26815.
43. Rassmann A, Henke A, Jarasch N, Lottspeich F, Saluz HP, Munder T (2007) The human fatty acid synthase: a new therapeutic target for coxsackievirus B3-induced diseases? Antiviral Res 76(2): 150-158.
44. Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410(6824): 37-40.
45. Huttunen P, Hyypia T, Vihinen P, Nissinen L, Heino J (1998) Echovirus 1 infection induces both stress- and growth-activated mitogen-activated protein kinase pathways and regulates the transcription of cellular immediate-early genes. Virology 250(1): 85-93.
46. Tung WH, Sun CC, Hsieh HL, Wang SW, Horng JT, Yang CM (2007) EV71 induces VCAM-1 expression via PDGF receptor, PI3-K/Akt, p38 MAPK, JNK and NF-kappaB in vascular smooth muscle cells. Cell Signal 19(10): 2127-2137.
47. Guinea R, Carrasco L (1990) Phospholipid biosynthesis and poliovirus genome replication, two coupled phenomena. EMBO J 9(6): 2011-2016.
48. Fogg MH, Teterina NL, Ehrenfeld E (2003) Membrane requirements for uridylylation of the poliovirus VPg protein and viral RNA synthesis in vitro. J Virol 77(21): 11408-11416.
49. Feuer R, Mena I, Pagarigan R, Slifka MK, Whitton JL (2002) Cell cycle status affects coxsackievirus replication, persistence, and reactivation in vitro. J Virol 76(9): 4430-4440.
50. Knowles LM, Axelrod F, Browne CD, Smith JW (2004) A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2. J Biol Chem 279(29): 30540-30545.
51. Guerciolini R (1997) Mode of action of orlistat. Int J Obes Relat Metab Disord 21(Suppl 3): S12-S23.
52. Ballinger A, Peikin SR (2002) Orlistat: its current status as an anti-obesity drug. Eur J Pharmacol 440(2-3): 109-117.
53. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW (2004) Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64(6): 2070-2075.
54. Adhikari RP, Novick RP (2005) Subinhibitory cerulenin inhibits staphylococcal exoprotein production by blocking transcription rather than by blocking secretion. Microbiology 151(Pt 9): 3059-3069.
55. Chayakulkeeree M, Rude TH, Toffaletti DL, Perfect JR (2007) Fatty acid synthesis is essential for survival of Cryptococcus neoformans and a potential fungicidal target. Antimicrob Agents Chemother 51(10): 3537-3545.